Praluent (alirocumab subcutaneous injection − Regeneron) — Cigna

Initial criteria

• Patient is age ≥ 18 years
• Patient has had ONE of the following conditions or diagnoses (a, b, c, d, e, or f)

Reauthorization criteria

• Patient is currently receiving Praluent therapy and has previously met initial therapy criteria under the Coverage Review Department

Approval duration

1 year